Followers | 183 |
Posts | 25199 |
Boards Moderated | 14 |
Alias Born | 04/03/2002 |
Monday, October 14, 2019 11:24:04 AM
- Dance Biopharm signs an agreement with DarioHealth to integrate Dance's gentle mist smart inhaler into DarioHealth's platform allowing for automated, real-time treatment data through a mobile application
- Combined platforms have potential to improve patient engagement and compliance
DURHAM, North Carolina and NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Dance Biopharm Holdings, Inc., a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, announced today it has formed a strategic alliance with DarioHealth Corp. "Dario" (Nasdaq: DRIO), a leading, global digital therapeutics company, to expand access to a personalized digital health management platform for patients with chronic diseases. Under the terms of the agreement, Dance Biopharm will integrate its gentle mist smart inhaler into DarioHealth's digital therapeutics platform to provide patients automated, real-time treatment data through an advanced mobile application. Dario will immediately start the design of the integrated solution for Dance to accommodate clinical trials and, upon regulatory approval, any marketed solutions.
Dance Biopharm's smart inhaler paired with proprietary gentle mist biologic formulations allows for optimal and precise delivery of therapies through the lungs. The vibrating mesh within the device facilitates the transmission of a soft mist that allows for a lung deposition 2-4 times higher than conventional inhalers. In clinical trials, the device delivered a gentle mist formulation of human insulin with a faster drug onset and comparable duration to subcutaneous delivery of a rapid insulin (Humalog) in patients with type 2 diabetes (T2D). Dance is also advancing a convenient inhalable pre-meal GLP-1 receptor agonist to improve postprandial glucose control in T2D patients.
Dario's digital therapeutics platform combines data analytics, high-quality software and personalized coaching to empower individuals with information to make healthy behavioral changes. The user-centric platform is comprised of MyDario™, a mobile application that is data-driven, with an all-in-one blood glucose monitoring system and an optional connected blood pressure monitoring system. It is complemented by DarioEngage™, a healthcare solutions platform for health and wellness providers to customize and integrate a patient's data into their care continuum.
"We are excited to partner with DarioHealth in empowering patients to take charge of their chronic illness. This platform is well established in the digital therapeutics space and has demonstrated positive behavior change in patients with chronic diseases through its user-centered approach," said Anne Whitaker, chief executive officer of Dance Biopharm. "We share a similar goal of adapting our platforms to chronic diseases beyond diabetes. Dance Biopharm is exploring opportunities to pair the smart inhaler with gentle mist biologic formulations beyond insulin. Our initial focus is on rare and severe diseases in the endocrinology, respiratory, and cardiovascular space, where our platform and expertise present a unique opportunity to achieve better treatment efficiency."
"Diabetes is a complex chronic condition that evolves over time, making real-time, streamed patient data essential to care," said Erez Raphael, chief executive officer of DarioHealth. "Through this strategic alliance, we are excited to expand the potential for our patient-centered, diabetes care and management solutions by integrating the smart inhaler, optimized to deliver a gentle mist formulation of insulin through the lungs, into our digital therapeutics platform, which includes blood glucose and blood pressure monitoring systems. Our goal is to place control of diabetes management directly into the hands of our users and, pending completion of clinical trials and regulatory approval, we believe that this alliance will help advance that critical objective."
About Dance Biopharm
Dance Biopharm is a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies. Our gentle mist inhaler is designed with smart technology to optimize the precise delivery of biologic therapies through the lungs. We are building a diverse pipeline of inhaled biologic products with initial focus on rare and severe diseases in the endocrinology, respiratory and cardiovascular space, where our platform and expertise present a unique opportunity to achieve better treatment efficiency. We have initiated development programs in glucagon-like peptide-1 (GLP-1), parathyroid hormone (PTH) and human growth hormone (HGH).
For more information, visit: https://www.dancebiopharm.com.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, we empower individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Our cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario™ mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, please go to: http://mydario.com/
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate," or "continue" are intended to identify forward-looking statements. For example, when the Company discusses the integration of Dance Biopharm's gentle mist inhaler with its digital platform, that Dario will immediately start the design of the integrated solution for Dance to accommodate clinical trials and, upon regulatory approval, any marketed solutionsand the belief that Dario's alliance with Dance, pending completion of clinical trials and regulatory approval, will help advance the critical objective of placing control of diabetes management directly into the hands of its users, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact:
Claudia Levi
Content & Communications Manager
claudia@mydario.com
+1.347.767.4220
Media Inquiries:
Catherine Polisi Jones
Polisi Jones Communications
cjones@polisijones.com
+1.917.330.8934
Gloria Gasaatura
LifeSci Public Relations
ggasaatura@lifescipublicrelations.com
https://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg
https://c212.net/c/img/favicon.png?sn=LN68014&sd=2019-09-11 View original content to download multimedia:http://www.prnewswire.com/news-releases/dance-biopharm-partners-with-dariohealth-to-expand-access-to-digital-therapeutics-platform-for-patients-with-chronic-diseases-300915954.html
SOURCE DarioHealth Corp.; Dance Biopharm Holdings, Inc.
Recent DRIO News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 08:05:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:37:42 PM
- Dario Introduces Integration of Twill Behavioral Health Capabilities into Cardiometabolic Health Solution to Enhance Member Engagement and Outcomes • PR Newswire (US) • 09/12/2024 12:30:00 PM
- Dario Publishes New Research Revealing How Physical Activity Mediates the Impact of Depression on Blood Glucose Levels in Individuals with Diabetes or Prediabetes • PR Newswire (US) • 09/10/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 10:00:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2024 10:12:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:05:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:01:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:01:15 PM
- DarioHealth Reports Second Quarter 2024 Financial and Operating Results • PR Newswire (US) • 08/08/2024 10:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 10:05:39 AM
- DarioHealth to Report Second Quarter 2024 Results on Thursday, August 8th • PR Newswire (US) • 07/30/2024 12:30:00 PM
- Dario Expands GLP-1 Solution Client Base with New Employer Contract • PR Newswire (US) • 07/16/2024 12:30:00 PM
- Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1 • PR Newswire (US) • 06/25/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:02:27 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:01:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 12:30:15 PM
- Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer • PR Newswire (US) • 06/05/2024 12:30:00 PM
- DarioHealth Reports First Quarter 2024 Financial and Operating Results • PR Newswire (US) • 05/15/2024 10:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 10:06:09 AM
- DarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th • PR Newswire (US) • 05/07/2024 12:30:00 PM
- Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes • PR Newswire (US) • 04/25/2024 12:30:00 PM
- Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution • PR Newswire (US) • 04/18/2024 12:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM